Brainstorm Cell Therapeutics traded at $1.05 this Tuesday September 8th. Looking back, over the last four weeks, Brainstorm Cell Therapeutics lost 35.32 percent. Over the last 12 months, its price rose by 47.89 percent. Looking ahead, we forecast Brainstorm Cell Therapeutics to be priced at 1.01 by the end of this quarter and at 0.95 in one year, according to Trading Economics global macro models projections and analysts expectations.
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is focused on development of cellular therapies for the treatment of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD) and other neurodegenerative diseases. The Company offers its services through NurOwn platform. Its BrainStorm Cell Therapeutics Ltd. (Israeli Subsidiary) holds rights to commercialize the technology, NurOwn. Its NurOwn platform leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.